CIMT 2023: report on the 20th Annual Meeting of the Association for Cancer Immunotherapy.

Dallmann, J; Freitag, J; Jung, C; Khinvasara, K; Merz, L; Peters, D; Schork, M; Beck, J D

Dallmann, J; Freitag, J; Jung, C; Khinvasara, K; Merz, L; Peters, D; Schork, M; Beck, J D.

Afiliación

Dallmann J; Immunotherapies & Preclinical Research, BioNTech SE, Mainz.
Freitag J; TRON-Translational Oncology, University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany.
Jung C; BioNTech Cell & Gene Therapies GmbH, Mainz.
Khinvasara K; TRON-Translational Oncology, University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany.
Merz L; TRON-Translational Oncology, University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany.
Peters D; Immunotherapies & Preclinical Research, BioNTech SE, Mainz.
Schork M; TRON-Translational Oncology, University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany.
Beck JD; Immunotherapies & Preclinical Research, BioNTech SE, Mainz.

Immunooncol Technol ; 20: 100397, 2023 Dec.

Article en En | MEDLINE | ID: mdl-37876518

ABSTRACT

ABSTRACT

The Association for Cancer Immunotherapy (CIMT) celebrated the 20th anniversary of the CIMT Annual Meeting. CIMT2023 was held 3-5 May 2023 in Mainz, Germany. 1051 academic and clinical professionals from over 30 countries attended the meeting and discussed the latest advances in cancer immunology and immunotherapy research. This report summarizes the highlights of CIMT2023.

Palabras clave

CIMT; cancer immunotherapy; cellular therapy; immune escape; personalized therapy; tumor microenvironment

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Immunooncol Technol Año: 2023 Tipo del documento: Article